Peerview Heart Lung & Blood Cme/cne/cpe Audio Podcast

Go online to PeerView.com/AKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses current and emerging interventions to reduce morbidity and mortality due to cerebral edema in patients with LHI. Upon completion of this activity, participants should be better able to: Apply evidence-based strategies for evaluation and management of large hemispheric infarction (LHI), Recognize the latest clinical trial data evaluating emerging therapy in the management of LHI and how this data applies to current practice

Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides

Go online to PeerView.com/XAC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium held during the Oncology Nursing Society’s (ONS) 44th Annual Congress, a panel of expert nurse faculty use a MasterClass/case-forum design to offer an in-depth review of BTK inhibitors, their therapeutic applications in B-cell malignancies, and the core nurse-focused practice issues that are central to the further integration of BTK inhibitors into treatment plans for patients with cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), among other B-cell disorders. Upon completion of this activity, participants will be able to: Summarize updated safety and efficacy evidence about first- and second-generation BTK inhibitors in the management of B-cell cancer, Cite dosing considerations, administration strategies, and treatment schedules of BTK inhibitors for the management of newly diagnosed or refract

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanism

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, includ

Go online to PeerView.com/CXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The best practices for management of patients with EGFR-mutant NSCLC continue to evolve as a result of advances in molecular testing and targeted treatment. Understanding what, when, and how to test, as well as how to select therapy, throughout the continuum of advanced NSCLC is paramount. In this activity, based on a recent live symposium held in San Diego, California, experts in EGFR-mutant NSCLC provide a concise but comprehensive overview of all the recent key evidence and new research directions and provide practical guidance for how to navigate clinical decisions in EGFR-mutant NSCLC in different settings and patient populations. Upon completion of this activity, participants will be able to: Discuss the latest recommendations for tissue- and blood-based molecular testing to evaluate EGFR mutation status in patients with advanced/metastatic NSCLC, Assess the characteristic

Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, hea

Go online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and address several ongoing clinical questions from the choice of novel induction and maintenance options to minimal residual disease monitoring and the use of newer therapeutic platforms for post-transplant relapsed disease. Upon completion of this activity, participants should be better able to: Summarize evidence regarding the safety, efficacy, and current clinical role of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma, Develop personalized inductio

Go online to PeerView.com/SXH860 to view the entire program with slides. In this activity, based on a live symposium held during the 2019 Transplantation and Cellular Therapy (TCT) Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in hematology-oncology explore new developments related to the changing clinical consensus for managing veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) as a post-transplant complication. In this program, the panelists will share their views on VOD pathophysiology and proposed revisions to diagnostic and severity grading criteria, while providing guidance on practical issues related to the selection and use of novel treatments for VOD. Ultimately, the experts present a picture of modern VOD management in which diagnoses can be accurately and rapidly made and where a diversity of disease presentations (including in adult and pediatric patients) can be e

Go online to PeerView.com/ZGE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hematologic malignancies, including in the context of hematopoietic stem cell transplantation (HCT). The expert panel also shares personal experiences from their practice or research on relevant patient cases to guide learners on how to effectively impact treatment care and improve outcomes for patients with leukemia and lymphoma. Upon completion of this activity, participants should be better able to: Summarize the anticancer mechanism and the latest evidence on the efficacy and safety of adoptive immunotherapy with chimeric antigen

Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn’t have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-relate

Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML w

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case s

Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings and how to manage treatment-related adverse effects associated with emerging agent classes. Upon completion of this activity, participants should be better able to: Cite updated data about the efficacy and safety of novel agent classes and next-generation therapeutics in multiple myeloma, including proteasome inhibitors, IMiDs, novel antibodies, immunotherapies, and epigenetic agents, among others, Develop customized therapy for patients with newly diagnosed multiple myeloma, including elderly patients, individuals eligi

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, amo

Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice

Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists

The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care

Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do